Mostrar el registro sencillo del ítem

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker

dc.contributor.authorManzine P.R.
dc.contributor.authorEttcheto M.
dc.contributor.authorCano A.
dc.contributor.authorBusquets O.
dc.contributor.authorMarcello E.
dc.contributor.authorPelucchi S.
dc.contributor.authorDi Luca M.
dc.contributor.authorEndres K.
dc.contributor.authorOlloquequi J.
dc.contributor.authorCamins A.
dc.contributor.authorCominetti M.R.
dc.date.accessioned2020-09-02T22:22:20Z
dc.date.available2020-09-02T22:22:20Z
dc.date.issued2019
dc.identifier10.1016/j.biopha.2019.108661
dc.identifier.citation113, , -
dc.identifier.issn07533322
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5199
dc.descriptionAlzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates. © 2019 Elsevier Masson SAS
dc.language.isoen
dc.publisherElsevier Masson SAS
dc.subjectADAM10
dc.subjectAlzheimer's disease
dc.subjectNatural compounds
dc.subjectPharmaceutical
dc.subjectα-Secretase
dc.subject(6) gingerol
dc.subjectADAM10 endopeptidase
dc.subjectalpha secretase
dc.subjectbryostatin 1
dc.subjectcryptotanshinone
dc.subjectcurcumin
dc.subjectepigallocatechin gallate
dc.subjectligustilide
dc.subjectnatural product
dc.subjectretinoid
dc.subjectADAM10 endopeptidase
dc.subjectADAM10 protein, human
dc.subjectamyloid beta protein
dc.subjectamyloid precursor protein
dc.subjectbiological marker
dc.subjectcatechin
dc.subjectGinkgo biloba extract
dc.subjectmembrane protein
dc.subjectneuroprotective agent
dc.subjectplant extract
dc.subjectsecretase
dc.subjectAlzheimer disease
dc.subjectdrug mechanism
dc.subjecthuman
dc.subjectneuroprotection
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectprotein function
dc.subjectprotein targeting
dc.subjectReview
dc.subjecttreatment outcome
dc.subjectAlzheimer disease
dc.subjectanalogs and derivatives
dc.subjectmetabolism
dc.subjectADAM10 Protein
dc.subjectAlzheimer Disease
dc.subjectAmyloid beta-Peptides
dc.subjectAmyloid beta-Protein Precursor
dc.subjectAmyloid Precursor Protein Secretases
dc.subjectBiomarkers
dc.subjectCatechin
dc.subjectHumans
dc.subjectMembrane Proteins
dc.subjectNeuroprotective Agents
dc.subjectPlant Extracts
dc.titleADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85062227996.pdf
Tamaño:
3.384Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem